Category: Stent Wars
The FDA grants pre-market approval to Boston Scientific's next-generation Promus Premier coronary stent.
Boston Scientific (NYSE:BSX) said the FDA granted pre-market approval for its next-generation coronary stent, the Promus Premier.
Natick, Mass.-based Boston Scientific said it plans an immediate release for the Promus Premier, a drug-eluting stent made of a platinum-chromium alloy coated with everolimus.
The U.S. Court of Appeals for the Federal Circuit declines to revisit its decision to uphold a lower court's decision to invalidate patents for drug-eluting coronary stent technology.
A federal appeals court last week declined to revisit its decision to uphold the invalidation of patents covering drug-eluting stent technology.
Boston Scientific agrees to pay an undisclosed amount to settle patent infringement cases against OrbusNeich in the U.S. and Europe over coronary stent technology.
Boston Scientific (NYSE:BSX) agreed to pay an undisclosed amount to put its long-running patent war with OrbusNeich Medical to rest.
Boston Scientific finishes enrolls the last of 1,684 patients in the Evolve II trial of its Synergy drug-eluting stent.
Boston Scientific (NYSE:BSX) said it finished enrolling 1,684 patients in a clinical trial of its next-generation Synergy drug-eluting stent, aiming to use the data to back regulatory nods in the U.S. and Canada.
Medinol, which wrung a $750 million patent infringement decision from Boston Scientific in 2005, sues Johnson & Johnson's Cordis stent making arm.
Cordis Corp., the stent-making arm of Johnson & Johnson (NYSE:JNJ), got out of the coronary stent game 2 years go, but that's not stopping Israeli medical device company Medinol from suing Cordis for patent infringement with the Cypher and Cypher Select stents it no longer makes.
Boston Scientific's latest legal updates provides some insight into a possible end in the long-running Guidant battles, a locking of arms in the Guidezilla disputes and minor progress in a few other litigations.
Medical device giant Boston Scientific (NYSE:BSX) listed no fewer than a dozen legal battles in its latest financial report, notching some wins, some losses and some seemingly circuitous fights without end.
A 2-year study comparing drug-eluting stents from industry titans Medtronic and Abbott report statistically similar outcomes for patients.